Journal of Pharmacology and Experimental Therapeutics
November 1, 1995
Piotr Popik, Richard T. Layer, Linda H. Fossom et al.
100 citations
Ibogaine blocks NMDA receptors in a voltage-dependent manner, with a Ki of 2.3 µM at -60 mV in hippocampal cultures, and competitively inhibits [3H]TCP binding to rat forebrain homogenates (Ki, 1.5 µM). It also blocks glutamate-induced cell death in neuronal cultures (IC50, 4.5 µM). At doses that interfere with drug-seeking behaviors, ibogaine substitutes as a discriminative stimulus (ED50, 64.9 mg/kg) in mice trained to discriminate dizocilpine from saline. Ibogaine reduces naloxone-precipitated jumping in morphine-dependent mice (ED50, 72 mg/kg), an effect abolished by glycine pretreatment. These findings link ibogaine's NMDA antagonist actions to its ability to reduce morphine dependence.
Pharmacology, Biochemistry and Behavior
April 22, 2020
J. Witkin, J. Kranzler, K. Kaniecki et al.
33 citations
The (R)-ketamine enantiomer may offer a safer treatment for substance abuse disorder by reducing withdrawal symptoms and drug-seeking behavior without causing negative mood or anhedonia. In experiments with morphine-dependent rats, (R)-ketamine alleviated withdrawal signs and blocked morphine-induced place preference in mice without producing place preference itself. Unlike S-ketamine, (R)-ketamine did not induce anhedonia in rats. These findings suggest (R)-ketamine could dampen withdrawal and drug liking without the dissociative or mood-related side effects that limit current therapies, supporting further preclinical and clinical investigation.
Psychopharmacology
March 2, 2022
Piotr Popik, Adam S. Hogendorf, Ryszard Bugno et al.
30 citations
Time underestimation caused by (S)-ketamine may be linked to its antidepressant effects, but this came with severe behavioral disruption. The authors propose that behavioral disruption induced by psychedelics objectively indicates their psychotomimetic-like actions.
Journal of Psychopharmacology
October 16, 2023
Maciej Koniewski, Piotr Popik, Natalia Malikowska‐racia et al.
6 citations
Psilocybin, but not LSD, produced an immediate antidepressant-like effect in rats tested on a differential reinforcement of low-rate responding (DRL 72s) schedule, shown by increased reinforced presses and response efficiency. Neither drug showed lasting effects up to four weeks after administration. The DRL 72s test, which reliably distinguishes antidepressants from other psychoactive drugs, detected only acute changes. These results suggest that detecting sustained antidepressant-like effects in rodents may require new behavioral methods, and question whether prolonged efficacy observed in humans depends on the psychotherapy typically paired with psychedelic treatment.
Figshare
January 1, 2021
Piotr Popik, Adam S. Hogendorf, Ryszard Bugno et al.
No Summary